* INNATE PHARMA *
1999 - Méditerranée
Marseille
www.innate-pharma.com Discovery, Drugs
Key words: Immuno-therapy, Immuno-modulators, Toll-like receptors (TLR), Cancer, IPH 4201
Mission: to develop first in class drugs targeting the innate immune system
Clients: Prescribers
info@innate-pharma.fr
Age: 10 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS | | Start-up |
Managing Dir.-CEO: Brailly (Hervé) [co-founder, born 1961, Ph.D., ex-Immunotech-Beckman-Coulter]
Sc.Dir.-CSO: Romagné (François) [Ph.D., co-founder, ex-Immunotech-Beckman-Coulter]
Clin.Dir.-CMO: Rozencweig (Marcel) [M.D., ex-BMS]
Fin.Dir.-CFO: Boissel (Stéphane) [ex-Lazard]
BusDev: Shah (Hemansu) [Ph.D., MBA, ex-GPC Biotech, BMS, J&J]
Financers (Hist.): Sofinnova Partners, Auriga Partners, GIMV, Alta Partners, Gilde Biotech & Nutrition, Pechel Industries, Innoveris, Quilvest, NIF Ventures, Novo-Nordisk, Public | Turnover (M€) : 8.7 (2007), 6.2 (2006)
Total funding (M€) : 125.3
Last funding (M€) : 23.1
Focus : Cancers
Position : Clinical
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME | | 2009 .12 | 5th round-financing : 23.1 M€, by FSI (for 11 M€) and previous investors (Novo Nordisk and Alta Partners) | RFINE | [10 years] |
| 2009 .08 | Clinical trial (phase II, beginning) for monoclonal antibody IPH 2101, supported by 2.9 M€ financing from Oséo | CLIN | [9 years] |
| 2009 .06 | Clinical trial (phase IIa, positive) for IPH1101 in type C Hepatitis | CLIN | [9 years] |
| 2009 .05 | Launch of Platine, a joint immuno-monitoring platform, by 5 partners (Innate Pharma, Transgene, ImmunID, Inserm and Cancer Centre Léon-Bérard), based in Lyon | MKTG | [9 years] |
| 2009 .01 | Partnering research agreement with Vivalis to produce IPH 4101 with EB66 for clinical trials (Oseo debt financing grant of 3.0 M€ for Innate Pharma) | R&D | [9 years] |
| 2008 .04 | Set-up of US subsidiary (operations) in New York State | ORGC | [8 years] |
| 2008 .02 | Set-up of 2 subsidiaries (trade, production) in France | ORGC | [8 years] |
| 2007 .05 | Nomination : Gilles Brisson, new Board Chairman, ex-Chairman Supervisory Board at Aventis Pharma France | ORGN | [7 years] |
| 2007 .01 | Launch of PGX Predict (diagnostics) by Clinical Data Inc., US partner | MKTG | [7 years] |
| 2006 .11 | Listing on Eurolist by Euronext Paris : 33.7 M€ | PBO | [7 years] |
| 2006 .00 | 4th round-financing : 10.0 M€, by Novo Nordisk | RFIND | [6 years] |
| 2006 .06 | Licensing-in of lead compound (TLR) from Schering-Plough | LICIN | [6 years] |
| 2006 .03 | Licensing-out to Novo Nordisk (total of 15.0 M€ equity investment, including 2003 deal) | LICOUT | [6 years] |
| 2004 .07 | 3nd round-financing : 15.0 M€, by Novo Nordisk, Quilvest and NIF Ventures | RFINC | [4 years] |
| 2003 .11 | Licensing-out to Novo Nordisk for the generation of a new therapeutic class of immuno-modulatory antibodies targeting natural killer (NK) cells | LICOUT | [4 years] |
| 2002 .08 | 2nd round-financing : 20.0 M€, by Alta Partners and AXA P.E., with Gilde Biotech & Nutrition, Pechel Industries, Innoveris | RFINB | [2 years] |
| 2002 .05 | Clinical trial (phase I) for Innacell and Phosphotim (beginning) | CLIN | [2 years] |
| 2002 .02 | Financing (no interest loan) : 2.0 M€, by ANVAR, to support initial clinical trials | DEBT | [2 years] |
| 2000 .04 | 1st round-financing : 4.5 M€, led by Sofinnova Partners, with Auriga Partners, GIMV | RFINA | [0 year] |
| 1999 .10 | Company founded by 4 European Scientists, pioneers in the field of innate immunity (Alessandro Moretta, Marc Bonneville, Jean-Jacques Fournier and Eric Vivier) and 2 managers from the biopharmaceutical industry (Hervé Brailly and François Romagné) | ORGF | [0 year] | Actualisation / Updating: 04-Janv-2010 |
|
